Albini Edward C.'s most recent trade in Sutro Biopharma Inc was a trade of 8,750 Common Stock done . Disclosure was reported to the exchange on March 5, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 8,750 | 135,675 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 8,750 | 0 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.36 per share. | 05 Mar 2025 | 3,594 | 132,081 (0%) | 0% | 1.4 | 4,888 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 9,125 | 130,673 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 9,125 | 9,125 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.42 per share. | 04 Mar 2025 | 3,748 | 126,925 (0%) | 0% | 1.4 | 5,322 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 17,250 | 51,750 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 17,250 | 131,868 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.59 per share. | 01 Mar 2025 | 10,320 | 121,548 (0%) | 0% | 1.6 | 16,409 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 7,875 | 15,750 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 7,875 | 114,618 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 69,000 | 69,000 | - | - | Restricted Stock Units (RSUs) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 68,000 | 68,000 | - | - | Stock Option (Right to Buy Common Stock) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 51,000 | 51,000 | - | - | Restricted Stock Units (RSUs) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 8,750 | 109,843 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 8,750 | 8,750 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.54 per share. | 05 Mar 2024 | 3,100 | 106,743 (0%) | 0% | 4.5 | 14,074 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 9,125 | 104,565 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 9,125 | 18,250 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.79 per share. | 04 Mar 2024 | 3,472 | 101,093 (0%) | 0% | 4.8 | 16,631 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 7,875 | 98,667 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 7,875 | 23,625 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.95 per share. | 01 Mar 2024 | 3,227 | 95,440 (0%) | 0% | 5.0 | 15,974 | Common Stock |
Sutro Biopharma Inc | Albini Edward C. | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 5,250 | 0 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Albini Edward C. | CFO AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 5,250 | 92,943 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | C. Edward Albini | CFO AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.99 per share. | 29 Jan 2024 | 2,151 | 90,792 (0%) | 0% | 5.0 | 10,733 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 47,000 | 47,000 | - | - | Stock Option (right to buy Common Stock) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 31,500 | 31,500 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 9,125 | 27,375 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 9,125 | 85,531 (0%) | 0% | - | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 8,750 | 17,500 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 8,750 | 94,281 (0%) | 0% | - | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.79 per share. | 03 Mar 2023 | 6,588 | 87,693 (0%) | 0% | 5.8 | 38,145 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2023 | 45,698 | 0 | - | - | Stock Option (right to buy) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.81 per share. | 13 Feb 2023 | 45,698 | 76,406 (0%) | 0% | 5.8 | 265,414 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 5,250 | 32,848 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2023 | 5,250 | 5,250 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.50 per share. | 27 Jan 2023 | 2,140 | 30,708 (0%) | 0% | 7.5 | 16,050 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 42,000 | 42,000 | - | - | Stock Option (right to buy Common Stock) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 36,500 | 36,500 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 8,750 | 30,743 (0%) | 0% | - | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 8,750 | 26,250 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.17 per share. | 04 Mar 2022 | 3,145 | 27,598 (0%) | 0% | 8.2 | 25,695 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2022 | 5,250 | 10,500 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2022 | 5,250 | 24,144 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.39 per share. | 29 Jan 2022 | 2,151 | 21,993 (0%) | 0% | 10.4 | 22,349 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2021 | 7,174 | 21,374 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2021 | 7,174 | 0 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.23 per share. | 24 Sep 2021 | 2,480 | 18,894 (0%) | 0% | 19.2 | 47,690 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy Common Stock) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2021 | 35,000 | 35,000 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 5,250 | 16,326 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 5,250 | 15,750 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.15 per share. | 29 Jan 2021 | 2,126 | 14,200 (0%) | 0% | 22.2 | 47,091 | Common Stock |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2020 | 7,174 | 7,174 | - | - | Restricted Stock Unit (RSU) | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2020 | 7,174 | 13,556 (0%) | 0% | 0 | Common Stock | |
Sutro Biopharma Inc | Edward C. Albini | CFO and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.30 per share. | 25 Sep 2020 | 2,480 | 11,076 (0%) | 0% | 10.3 | 25,544 | Common Stock |